Nutra Pharma Statistics
Total Valuation
Nutra Pharma has a market cap or net worth of 715,973. The enterprise value is 13.06 million.
| Market Cap | 715,973 |
| Enterprise Value | 13.06M |
Important Dates
The next estimated earnings date is Friday, November 20, 2026.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nutra Pharma has 7.16 billion shares outstanding. The number of shares has increased by 3.11% in one year.
| Current Share Class | 7.16B |
| Shares Outstanding | 7.16B |
| Shares Change (YoY) | +3.11% |
| Shares Change (QoQ) | +0.69% |
| Owned by Insiders (%) | 0.95% |
| Owned by Institutions (%) | 0.00% |
| Float | 7.09B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.77 |
| PB Ratio | -0.03 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 50.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.02
| Current Ratio | 0.02 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -11.77 |
| Interest Coverage | -3.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -138.05% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 7.77% |
| Weighted Average Cost of Capital (WACC) | 21.17% |
| Revenue Per Employee | 43,151 |
| Profits Per Employee | -903,416 |
| Employee Count | 6 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 6.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9,900.00% in the last 52 weeks. The beta is 60.53, so Nutra Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 60.53 |
| 52-Week Price Change | +9,900.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 47.00 |
| Average Volume (20 Days) | 301,674 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Nutra Pharma had revenue of 258,906 and -5.42 million in losses. Loss per share was -0.00.
| Revenue | 258,906 |
| Gross Profit | 125,669 |
| Operating Income | -1.64M |
| Pretax Income | -5.42M |
| Net Income | -5.42M |
| EBITDA | -1.63M |
| EBIT | -1.64M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 17,600 in cash and 12.35 million in debt, with a net cash position of -12.33 million or -0.00 per share.
| Cash & Cash Equivalents | 17,600 |
| Total Debt | 12.35M |
| Net Cash | -12.33M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -21.21M |
| Book Value Per Share | -0.00 |
| Working Capital | -21.23M |
Cash Flow
| Operating Cash Flow | -1.05M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 10,200 |
| Net Borrowing | 970,533 |
| Free Cash Flow | -1.05M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | 48.54% |
| Operating Margin | -632.16% |
| Pretax Margin | -2,093.61% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nutra Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.11% |
| Shareholder Yield | -3.11% |
| Earnings Yield | -757.08% |
| FCF Yield | -146.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 18, 2015. It was a reverse split with a ratio of 0.025.
| Last Split Date | May 18, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.025 |
Scores
Nutra Pharma has an Altman Z-Score of -234.98 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -234.98 |
| Piotroski F-Score | 2 |